First Tracks Bio Receives Positive FDA Feedback for Rosnilimab, Explores Strategic Options
TRAX sits 23% above its 52-week low of $14.79.
Summary
First Tracks Biotherapeutics announced its first quarter 2026 financial results and provided a significant business update. The company reported completing an End-of-Phase 2 meeting with the FDA for rosnilimab, receiving constructive feedback on a registrational Phase 3 path in rheumatoid arthritis. This positive regulatory interaction de-risks the asset's development. Furthermore, First Tracks is actively assessing strategic options for rosnilimab, including global partnerships, out-licensing, or asset financing, which could provide non-dilutive capital or a significant deal. The company also provided updates on its ANB033 program, with top-line Phase 1b data for celiac disease anticipated in Q4 2026 and for eosinophilic esophagitis in mid-2027. Financially, the company launched with $180 million in cash and cash equivalents post-separation, though it reported an increased net loss of $50.5 million for the quarter. Traders will be watching for the outcome of the strategic review for rosnilimab and the upcoming ANB033 data readouts.
At the time of this announcement, TRAX was trading at $18.16 on NASDAQ in the Life Sciences sector. The 52-week trading range was $14.79 to $26.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.